Literature DB >> 17351980

Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.

Sophy Zheng1, Ilya V Ulasov, Yu Han, Matthew A Tyler, Zeng B Zhu, Maciej S Lesniak.   

Abstract

BACKGROUND: Malignant gliomas remain refractory to Ad5-mediated gene therapy due to deficiency of the coxsackie adenovirus receptor on tumor cells. The purpose of this study was to evaluate whether changes in adenoviral tropism can enhance gene transfer in the context of malignant glioma.
METHODS: We have identified several receptors that are over-expressed on tumor cells and created a series of pseudotyped Ad5 vectors that recognize these receptors: Ad5-RGD which binds alpha(v)beta3/alpha(v)beta5 integrins; Ad5/3 which contains adenovirus serotype 3 knob and binds to CD46; Ad5-Sigma which incorporates the reovirus sigma knob and binds to junctional adhesion molecule-1; and Ad5-pk7 which contains the polylysine motif and binds heparan sulfate proteoglycans. We also investigated the Ad5-CAV1 vector, which contains the knob of canine adenovirus type 1, a virus previously shown to infect glioma via an unknown mechanism. In this study, we compared these modified vectors for their ability to promote the expression of luciferase transgene both in vitro and in vivo.
RESULTS: Our results indicate that all five modified vectors attained higher mean luciferase activity vs. control. Among them, Ad5-CAV1 and Ad5-pk7 attained the highest transduction efficiency independent of different tumor lines or infection time. Ad5-Sigma and Ad5-pk7 also demonstrated the least nonspecific infection in normal human astrocytes. Most importantly, Ad5-pk7 achieved 1000-fold increased transgene expression in human glioma xenografts in vivo.
CONCLUSIONS: These results indicate that modifications of adenoviral tropism can enhance gene transfer in tumors that are poorly susceptible to adenoviral vectors and warrant further development of Ad5-pk7 for glioma gene therapy. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351980     DOI: 10.1002/jgm.1008

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  30 in total

1.  Neural stem cell-mediated delivery of oncolytic adenovirus.

Authors:  Julius W Kim; J Robert Kane; Jacob S Young; Alan L Chang; Deepak Kanojia; Shuo Qian; Drew A Spencer; Atique U Ahmed; Maciej S Lesniak
Journal:  Curr Protoc Hum Genet       Date:  2015-04-01

2.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

3.  A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma.

Authors:  Julius W Kim; J Robert Kane; Jacob S Young; Alan L Chang; Deepak Kanojia; Ramin A Morshed; Jason Miska; Atique U Ahmed; Irina V Balyasnikova; Yu Han; Lingjiao Zhang; David T Curiel; Maciej S Lesniak
Journal:  Hum Gene Ther       Date:  2015-08-11       Impact factor: 5.695

Review 4.  Directing systemic oncolytic viral delivery to tumors via carrier cells.

Authors:  Hiroshi Nakashima; Balveen Kaur; E A Chiocca
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-11       Impact factor: 7.638

Review 5.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

Review 6.  Stem cells as delivery vehicles for oncolytic adenoviral virotherapy.

Authors:  Justin Kranzler; Matthew A Tyler; Adam M Sonabend; Ilya V Ulasov; Maciej S Lesniak
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

7.  Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats.

Authors:  A M Sonabend; I V Ulasov; Y Han; C E Rolle; S Nandi; D Cao; M A Tyler; M S Lesniak
Journal:  Cancer Gene Ther       Date:  2008-11-14       Impact factor: 5.987

8.  A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.

Authors:  Suvobroto Nandi; Ilya V Ulasov; Cleo E Rolle; Yu Han; Maciej S Lesniak
Journal:  J Gene Med       Date:  2009-11       Impact factor: 4.565

9.  CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.

Authors:  L N Kaliberova; V Krendelchtchikova; D K Harmon; C R Stockard; A S Petersen; J M Markert; G Y Gillespie; W E Grizzle; D J Buchsbaum; S A Kaliberov
Journal:  Cancer Gene Ther       Date:  2009-04-10       Impact factor: 5.987

Review 10.  Adenovirus receptors and their implications in gene delivery.

Authors:  Anurag Sharma; Xiaoxin Li; Dinesh S Bangari; Suresh K Mittal
Journal:  Virus Res       Date:  2009-02-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.